
|Videos|November 14, 2013
Compounding Pharmacy Regulation and Office Use
David G. Miller, RPh, discusses concerns regarding the regulatory status of compounding medications for office use by physicians or dentists.
Advertisement
In this video, David G. Miller, RPh, executive vice president and CEO of the International Academy of Compounding Pharmacists (IACP), discusses his concern that in reaffirming section 503A of the Federal Food, Drug, and Cosmetic Act, H.R. 3204 (the Drug Quality and Security Act) would leave pharmacists who compound medications for office use by physicians and dentists in an ambiguous regulatory position. This video was recorded at the National Community Pharmacists Association 115th Annual Convention in Orlando.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
2
First-in-Human In Vivo CAR-T Therapy Shows Encouraging Activity in Relapsed/Refractory Multiple Myeloma
3
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
4
Darovasertib Plus Crizotinib Shows Striking Efficacy in HLA-A2–Negative Metastatic Uveal Melanoma, OptimUM-02 Results Show
5








































































































































